Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis.
Tanaka
Makoto
M
mak.tanaka@ono.co.jp
Mori
Hiroshi
H
Shimizu
Kiyoshi
K
Toshiyuki
Matsuoka
Yamamotoya
Hajime
H
Minamide
Toshiomi
T
Mori
Masamichi
M
Nozaki
Kazutoshi
K
Usui
Takashi
T
Shimokawa
Kenichiro
K
Suzuki
Hiromi
H
Aoyama
Koji
K
Kimoto
Aishi
A
Sasamata
Masao
M
Miyata
Keiji
K
D000818:Animals; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D016723:Bone Remodeling / Q000187:drug effects; D001862:Bone Resorption / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D019204:GTP-Binding Proteins / Q000378:metabolism; D051228:Geranyltranstransferase / Q000037:antagonists & inhibitors; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D008798:Mevalonic Acid / Q000378:metabolism; D010024:Osteoporosis / Q000188:drug therapy*; D016103:Spinal Fractures / Q000517:prevention & control
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; C087958:YM 529; D051228:Geranyltranstransferase; D019204:GTP-Binding Proteins; D008798:Mevalonic Acid